A further possible strategy to inhibit CYP51A1TM indirectly could be represented by the modulation of RNF185 activity, such as via gene therapy, for those cancers where it is underexpressed (i.e., HCC, PTC, prostate carcinoma). The gene discussed is RNF185; the disease is cancer.